Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of Obeticholic Acid in PBC with Hepatic Impairment
NCT03633227Phase 4Terminated
- Sponsor
- Intercept Pharmaceuticals
- Start
- Jun 2018
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 12
01
Overview
A Phase 4 trial of obeticholic acid in primary biliary cholangitis (PBC), sponsored by Intercept Pharmaceuticals. Started Jun 2018; status: terminated.
02
Drugs
obeticholic acid
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on NCT03633227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633227.